You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海思科(002653.SZ)獲得創新藥注射用HSK36273藥物臨牀試驗批准通知書
格隆匯 04-10 16:39

格隆匯4月10日丨海思科(002653.SZ)公佈,公司於近日收到國家藥品監督管理局下發的《藥物臨牀試驗批准通知書》。根據《中華人民共和國藥品管理法》及有關規定,經審查,2022年1月受理的注射用HSK36273符合藥品註冊的有關要求,同意本品開展“用於血液透析及術中患者的全身抗凝”的臨牀試驗。

注射用HSK36273為我公司研發的靜脈用抗凝血藥物,臨牀擬用於血液透析及術中患者的全身抗凝。其主要成分HSK36273為我公司於2019年自美國公司eXIthera引進(詳見公司於2019年4月2日披露的編號為2019-038號的公吿),是一種高效的小分子藥物,起效快、解離快,為高選擇XIa因子抑制劑。前期研究表明,療效與肝素相當,但安全性大大提高,其成功開發具有重要的臨牀和社會意義。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account